Gilead, Arcus expand research partnership to include inflammatory diseases
Arcus will receive an upfront payment of $35m and will commence research programs against up to four targets,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 May 23
Arcus will receive an upfront payment of $35m and will commence research programs against up to four targets,…
15 May 23
Rona Therapeutics will use its RAZOR platform to discover and identify siRNA lead compounds directed to a novel…
08 May 23
The biotechnology company has entered negotiations with a major global pharmaceutical company, for the development and commercialisation of…
03 May 23
Janssen will obtain an exclusive license to develop and commercialise CBMG’s C-CAR039 and C-CAR066 in geographic territories outside…
03 May 23
Under the agreement, Lundbeck will have access to Alloy Therapeutics’ antibody discovery services as well as its SeqImmune…
12 Apr 23
The DNase platform targets neutrophil extracellular traps to improve the outcomes of prevailing treatments, including immunotherapies
06 Apr 23
Under the agreement, Proxygen will receive an upfront payment of up to $2.55bn in research, development, and commercial…
04 Apr 23
BioNTech receives exclusive licenses from DualityBio for two experimental antibody-drug conjugate assets, DB-1303 and DB-1311, which are directed…
31 Mar 23
Brexafemme is a novel oral glucan synthase inhibitor that works with a distinct mechanism of action where it…
29 Mar 23
Bicycle Therapeutics will leverage its in-house phage platform to discover bicyclic peptide (Bicycle) to be developed into BRCs,…